Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 676

Sort by

Sort Order Select

Journal Articles

Simultaneous bone marrow involvement by CLL/SLL and LEF1/cyclin D1-positive metastatic melanoma

Kirill A. Lyapichev, Fatima Z. Jelloul

Blood (2020) 136 (2): 258.

https://doi.org/10.1182/blood.2020006057

Published: 2020

Journal Articles

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia

Matthew Lunning, Julie Vose, Loretta Nastoupil, Nathan Fowler, Jan A. Burger, William G. Wierda, Marshall T. Schreeder, Tanya Siddiqi, Christopher R. Flowers, Jonathon B. Cohen, Peter Sportelli, Hari P. Miskin, Michael S. Weiss, Susan O’Brien

Blood (2019) 134 (21): 1811–1820.

https://doi.org/10.1182/blood.2019002118

Published: 2019

Includes: Supplemental data

Journal Articles

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Gavin Cull, MB, BS, FRACP, FRCPA, David Simpson, MBChB, FRACP, FRCPA, Stephen Opat, Jan A. Burger, MD PhD, Judith Trotman, MBChB, FRACP, FRCPA, Paula Marlton, MBBS (Hons), FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, Javier Munoz, MD MS, FACP, John F. Seymour, MBBS, PhD FRACP, Andrew W. Roberts, MBBS, PhD, Ken Wu, PhD, Siminder Atwal, PhD, William Novotny, MD, Jane Huang, MD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 500.

https://doi.org/10.1182/blood-2019-125483

Published: 2019

Journal Articles

Lisocabtagene Maraleucel (liso-cel) Manufacturing Process Control and Robustness across CD19+ Hematological Malignancies

Jeffrey Teoh, PhD, Timothy G. Johnstone, PhD, Brian Christin, BS, Rachel Yost, Neil A. Haig, Mary Mallaney, Aditya Radhakrishnan, Heidi H. Gillenwater, MD, Tina Albertson, MD, Paul Guptill, Lauren F. Brown, Christopher G. Ramsborg, Ronald J. Hause, PhD, Ryan P. Larson, PhD

Blood (2019) 134 (Supplement_1): 593.

https://doi.org/10.1182/blood-2019-127150

Published: 2019

Journal Articles

Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib

Tanya Siddiqi, MD, Jacob D. Soumerai, MD, Kathleen A. Dorritie, MD, Deborah M. Stephens, DO, Peter A. Riedell, MD, Jon E. Arnason, MD, Thomas J. Kipps, MD PhD, Heidi H. Gillenwater, MD, Lucy Gong, PharmD, Jason A. Dubovsky, PhD, Julie Rytlewski, PhD, Lin Yang, William G. Wierda, MD PhD

Blood (2019) 134 (Supplement_1): 503.

https://doi.org/10.1182/blood-2019-127603

Published: 2019

Journal Articles

A Phase I/II Study of Lenalidomide Plus Obinutuzumab in Relapsed Indolent Lymphoma

Nathan H Fowler, MD, Loretta J. Nastoupil, MD MSc, Collin Chin, MBBS, Paolo Strati, MD, Fredrick B. Hagemeister, MD, Luis E. Fayad, MD, Jason R. Westin, MD, Sheryl G Forbes, Janine Arafat, Lei Feng, MS, Ranjit Nair, MBBS,MD, Raphael E Steiner, MD, Felipe Samaniego, MD, Sattva S Neelapu, MD

Blood (2019) 134 (Supplement_1): 348.

https://doi.org/10.1182/blood-2019-131045

Published: 2019

Journal Articles

Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial

Blood (2019) 134 (Supplement_1): 356.

https://doi.org/10.1182/blood-2019-123678

Published: 2019

Journal Articles

Safety, Tolerability and Efficacy of Orelabrutinib, Once a Day, to Treat Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia

Blood (2019) 134 (Supplement_1): 4319.

https://doi.org/10.1182/blood-2019-123331

Published: 2019

Journal Articles

Does Venetoclax Cause Vitiligo?

Sujatha Baddam, MD, Jorge Diaz Castro, MD

Blood (2019) 134 (Supplement_1): 5139.

https://doi.org/10.1182/blood-2019-130854

Published: 2019

Journal Articles

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial

Blood (2019) 134 (Supplement_1): 499.

https://doi.org/10.1182/blood-2019-125394

Published: 2019

Journal Articles

BTK Inhibitors Induce ABC-DLBCL Cell Apoptosis By Inhibiting CYLD Phosphorylation

Xin Xu

Blood (2019) 134 (Supplement_1): 5046.

https://doi.org/10.1182/blood-2019-126763

Published: 2019

Journal Articles

Efficacy and Safety of Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia

Zhijian Cao, MD, Jun Ma, MD PhD

Blood (2019) 134 (Supplement_1): 5478.

https://doi.org/10.1182/blood-2019-126686

Published: 2019

Journal Articles

Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Combined Analysis of Three Phase III Randomized Controlled Trials

Sriman Swarup, MDMBBS, Donald P. Quick, MD, Anita Sultan, MD, Nicholas D'Cunha, MD, Thura Win Htut, MBBS, MRCP, Pwint Phyu Hlaing, MD, Upama Sharma, Nimesh Adhikari, MD, Ye Aung, Myat Min Han, MD, Yin Mon Myat, MD, Fred Hardwicke, MD, Lukman Tijani, MD, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 5479.

https://doi.org/10.1182/blood-2019-123172

Published: 2019

Journal Articles

Decreased Thrombin Generation Potential in Lymphoma Patients Is Associated with Increased D-Dimer, CRP, Vwf and TNF-α. Interrelationship between Thrombogenesis and Inflammation

Fakiha Siddiqui, Emily Bontekoe, Darko Antic, PhD, Debra Hoppensteadt, PhD, Grigoris Gerotziafas, MD PhD, Jawed Fareed, PhD

Blood (2019) 134 (Supplement_1): 5239.

https://doi.org/10.1182/blood-2019-128440

Published: 2019

Journal Articles

Efficacy of Phosphatidylinositol 3-Kinase (PI3K) Inhibitors in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

Anita Sultan, MD, Bradley J. Grant, JD, Donald P. Quick, MD, Chandler Graf, Sriman Swarup, MDMBBS, Sriman Swarup, MDMBBS, Jonathan Kopel, BS, Thura Win Htut, MBBS, MRCP, Somedeb Ball, MD, Ei Moe Phyu, MD, Myat Min Han, MD, Yin Mon Myat, MD, Nicholas D'Cunha, MD, Myint Aung Win, MDMBBS, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 5480.

https://doi.org/10.1182/blood-2019-123231

Published: 2019

Journal Articles

Efficacy of Ibrutinib in Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Combined Analysis of Four Phase III Randomized Controlled Trials

Anita Sultan, MD, Chandler Graf, Donald P. Quick, MD, Sriman Swarup, MDMBBS, Jonathan Kopel, BS, Thura Win Htut, MBBS, MRCP, Nimesh Adhikari, MD, Myat Min Han, MD, Yin Mon Myat, MD, Sanjay Awasthi, MD, Lukman Tijani, MD, Nicholas D'Cunha, MD, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 5481.

https://doi.org/10.1182/blood-2019-123233

Published: 2019

Journal Articles

Cellular and Molecular Characterization of Breast Cancer Chemotherapy-Related B Cell Lymphomas

Madeline Rodriguez Valentin, PhD, Darwing Rivas, BSc, Vesna Jurecic, BSc, Alain Diaz, PhD, Richard Riley, PhD, Daniela Frasca, PhD, Roland Jurecic, PhD

Blood (2019) 134 (Supplement_1): 5241.

https://doi.org/10.1182/blood-2019-127252

Published: 2019

Journal Articles

Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Retrospective, Single-Institution Analysis Based on Risk Features and Debulking Strategy with Anti-CD20 Monoclonal Antibody

Ariel F Grajales-Cruz, MD, Julio Chavez, Virginia Olivia Volpe, MD, Jose Sandoval-Sus, MD, Bijal Shah, MD, Celeste Bello, MD, Lubomir Sokol, MD PhD, Shanel Fisher, Rajesh R Nair, PhD, Yun Seongseok, MD, Hayder Saeed, MD, Leidy Isenalumhe, MD, Elyce P. Turba, MSN, RN, Lisa Nodzon, PhD ARNP, AOCNP, Javier Pinilla Ibarz, MD PhD

Blood (2019) 134 (Supplement_1): 5484.

https://doi.org/10.1182/blood-2019-129260

Published: 2019

Journal Articles

ME-401-003 (TIDAL): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 Investigating Continuous and Intermittent Dosing Schedules in Patients with Relapsed/Refractory Follicular Lymphoma

Andrew D. Zelenetz, MD PhD, Pier Luigi Luigi Zinzani, MD, Henry Chan, MBChB, Christian Buske, MD PhD, Vincent Ribrag, David Cunningham, MD FRCP, FMedSci, Wojciech Jurczak, Pau Abrisqueta, MD PhD, Joanne Li, Igor Gorbatchevsky, MD, Jennifer R. Brown, MD PhD

Blood (2019) 134 (Supplement_1): 5244.

https://doi.org/10.1182/blood-2019-124326

Published: 2019

Journal Articles

Clinical Outcomes of Obinutuzumab Therapy across Non-Hodgkin Lymphoma Subtypes

Mitchell E. Hughes, PharmD, Esin C. Namoglu, B.S., Connie Suen, PharmD, Stephen J Schuster, MD, Jakub Svoboda, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, James N. Gerson, MD, Kyle Robinson, MD, Elise A. Chong, MD, Joanna M Rhodes, MD, Emily C. Ayers, MD, Alison W. Loren, MD MSCE, Edward A. Stadtmauer, MD FACP, Sunita Dwivedy Nasta, MD

Blood (2019) 134 (Supplement_1): 5247.

https://doi.org/10.1182/blood-2019-128148

Published: 2019

NARROW

Simultaneous bone marrow involvement by CLL/SLL and LEF1/cyclin D1-positive metastatic melanoma

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Lisocabtagene Maraleucel (liso-cel) Manufacturing Process Control and Robustness across CD19+ Hematological Malignancies

A Phase I/II Study of Lenalidomide Plus Obinutuzumab in Relapsed Indolent Lymphoma

Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial

Safety, Tolerability and Efficacy of Orelabrutinib, Once a Day, to Treat Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia

Does Venetoclax Cause Vitiligo?

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial

BTK Inhibitors Induce ABC-DLBCL Cell Apoptosis By Inhibiting CYLD Phosphorylation

Efficacy and Safety of Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia

Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Combined Analysis of Three Phase III Randomized Controlled Trials

Decreased Thrombin Generation Potential in Lymphoma Patients Is Associated with Increased D-Dimer, CRP, Vwf and TNF-α. Interrelationship between Thrombogenesis and Inflammation

Efficacy of Phosphatidylinositol 3-Kinase (PI3K) Inhibitors in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

Efficacy of Ibrutinib in Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Combined Analysis of Four Phase III Randomized Controlled Trials

Cellular and Molecular Characterization of Breast Cancer Chemotherapy-Related B Cell Lymphomas

Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Retrospective, Single-Institution Analysis Based on Risk Features and Debulking Strategy with Anti-CD20 Monoclonal Antibody

ME-401-003 (TIDAL): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 Investigating Continuous and Intermittent Dosing Schedules in Patients with Relapsed/Refractory Follicular Lymphoma

Clinical Outcomes of Obinutuzumab Therapy across Non-Hodgkin Lymphoma Subtypes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only